The Axis-D pen system is a disposable, variable dose injection device designed for applications with a 3ml cartridge.
Haselmeier develops and manufactures self-injection devices, proprietary designs, technology and intellectual property for the medical device industry.
Self-injection systems for the medical device industry
Haselmeier has more than four decades of experience with medical devices and comply with regulatory requirements to create, design and industrialise self-injection systems.
The company’s self-injection systems are used by pharmaceutical and biotechnology companies worldwide.
Haselmeier creates products that enable a convenient and comfortable self-injection experience by integrating patient feedback into the design of devices.
Early concepts are prototyped for testing and human factors studies capture the handling needs and skills of potential users. The company’s range of drug devices provides successful administration of the drug and a positive user experience.
Human factor studies
Haselmeier offers early-stage activities, including think-tank discussions, paper and product concepts and industrial designs, user handling review and risk-analysis, as well as prototyping of initial concepts up to functional devices.
The company also provides user focus groups and human factor studies for concept and prototype evaluation.
Successful development and industrialisation of drug delivery devices is dependent upon the execution of technical, regulatory and operational requirements.
Haselmeier specialises in qualified design control processes and certified systems using a network of partners and manufacturing operations for an efficient market introduction for drug delivery devices.
Commercial development and industrialisation services include regulatory expertise to support approval strategies and controlled design-to-manufacturing transfer, verification and validation.
Drug delivery devices for manufacturing
Haselmeier adheres to high standards for drug delivery devices to ensure reliable and reproducible manufacturing. Potential improvements are identified at all stages of the product’s lifecycle to provide a safe and state-of-the-art drug delivery device.
Haselmeier provides flexible and reliable manufacturing and lifecycle management using:
- Certified and modern production facilities and manufacturing processes
- Qualified personnel
- A strong network of sub-suppliers and manufacturing partners
- Continuous engineering and product improvement programme
- Innovation meetings to identify next product generation
Headquartered in Switzerland, Haselmeier has more than four decades of experience in the manufacture of self-injection devices. The products are produced in state-of-the-art facilities in Germany, Czech Republic and India.
Depicting strong brand imagery, Haselmeier’s injection devices are designed and industrialised by the company’s planning and development team. The company employs around 200 people internationally in offices in Europe, the US and India. They work together to manufacture successful products for the pharmaceutical and biotechnology industry.
The D-Flex injection pen can do more than previous pens. D-Flex can be configured for several fixed-dose values and is thus a variable fixed-dose pen.
Type 2 diabetes is a global health problem. According to expert estimates, the number of patients worldwide will increase by 48% by 2045.
As an innovative, strategic partner company, Haselmeier develops and produces customised, unique systems that are used worldwide.
Haselmeier has announced it will be developing a smart connected monitoring and support solution in a collaboration with Common Sensing.
The Haselmeier D-Flex is a disposable pen for use with 3ml cartridges.
The new Pergoveris® Pen by Haselmeier has received a positive assessment by Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA).
Haselmeier has announced Paul Jansen has been appointed as its senior advisor and member of the board of directors
Haselmeier's new D-Flex Just One has won the GOOD DESIGN™ Award.
Haselmeier has won German Brand Award 2016 following the GOOD DESIGN™ Award and the Red Dot Award: Product Design in 2015.
Based on Haselmeier's i-pen platform, launch of the 300 unit insulin pen BerliPen® areo 3 to the German market has been announced by Berlin-Chemie.
Haselmeier released GONAL-f® 2.0 after being approved by the European Medicines Agency (EMA).
The Haselmeier Group has decided to reinforce and reorganise its Executive Board.
The world's largest and fastest provider of information is the Internet.
Haselmeier has announced the opening of its new office in the Boott Cotton Mills at 126 John Street, Suite 11, Lowell, Massachusetts 01852.
Haselmeier is proud to announce another award for one of its products.
Haselmeier Group has won prizes for two of their products at the Good Design Awards.
Haselmeier has been able to successfully grow over the past few years, allowing the company to carve out a solid position in the market for medical devices.
Haselmeier has announced that Biocon, one of Asia's premier biotechnology companies, has just launched the INSUPen® EZ in India.